Inhalation

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Atmosphere, Urine, Medical Subject Headings, Marketing, Sinusitis, Agency, Pharyngitis, INN, Lower respiratory tract infection, Constipation, Infection, ATC, Pain, Blood, International, Chronic obstructive pulmonary disease, Cough, Bromide, Common, Headache, Nose, Language, Brain, FEV1, Periodic breathing, Mouth, Inhalation, Gestational sac, Heart, Inflammation, B cell, European Medicines Agency, Xerostomia, Select, Patient, Urinary tract infection, Safety, Anatomy, Muscarinic acetylcholine receptor, Throat, IIA, Umeclidinium bromide, Medical device

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Atmosphere, Urine, Medical Subject Headings, Marketing, Sinusitis, Agency, Pharyngitis, INN, Lower respiratory tract infection, Constipation, Infection, ATC, Pain, COPD, Blood, International, Chronic obstructive pulmonary disease, Bromide, Common, Headache, Nose, Cough, Language, Brain, FEV1, Periodic breathing, Mouth, Inhalation, Gestational sac, Heart, Inflammation, Wheeze, B cell, European Medicines Agency, Xerostomia, Select, Patient, Urinary tract infection, Safety, Anatomy, Muscarinic acetylcholine receptor, Throat, IIA, Umeclidinium bromide, Medical device

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

NanoPhoria Bioscience Publishes Groundbreaking Study in Major Cardiology Journal

Retrieved on: 
Tuesday, January 2, 2024
Research, Medical Devices, Surgery, Clinical Trials, Cardiology, Other Health, Biotechnology, General Health, Health, Science, Blood pressure, Heart rate, FESC, JACC, Injection, Disease, FACC, Massachusetts General Hospital, MD, Doctor of Philosophy, Heart failure, Inhalation, Animal, Cerebral edema, LTCC, American College, Patient, Facial muscles, Harvard Medical School, Journal, Medical device

NanoPhoria srl, a pre-clinical stage biotech company, is pleased to announce today the publication of a groundbreaking study in the field of cardiology, conducted using a clinically relevant pig model of heart failure.

Key Points: 
  • NanoPhoria srl, a pre-clinical stage biotech company, is pleased to announce today the publication of a groundbreaking study in the field of cardiology, conducted using a clinically relevant pig model of heart failure.
  • This significant piece of preclinical research, titled “Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure,” was published by our co-founders in the Journal of the American College of Cardiology (JACC), a prominent peer-reviewed medical journal.
  • Results confirming the therapeutic effect recapitulated ex vivo in cardiac myofibrils and biopsies from treated heart failure animals.
  • “Additionally, our research showcases a major advancement in the field of heart disease treatment.

VOZOL's latest upgrade, SWITCH PRO, will officially enter the European market in January 2024.

Retrieved on: 
Friday, December 29, 2023
SWITCH, Taste, Herbal cigarette, Immersion, Inhalation, Video game

SHENZHEN, China, Dec. 29, 2023 /PRNewswire/ -- Recognizing the growing demand for prefilled pod kit in the European vape market, and as a strategic move to cater to the changing preferences of European vape users, VOZOL is proud to announce the launch of a new product, Switch Pro, designed specifically for the European market. We are committed to bringing a refreshing experience to our users in the European market. While continuing the charm of the VOZOL switch series, this iteration also provides users with a more refined taste and a more elegant appearance.

Key Points: 
  • We are committed to bringing a refreshing experience to our users in the European market.
  • While continuing the charm of the VOZOL switch series, this iteration also provides users with a more refined taste and a more elegant appearance.
  • An innovative feature of the Switch Pro is its Visual Oil Chamber Replacement capability.
  • Drawing inspiration from the success of previous products like Switch Pro and Neon 800, VOZOL consistently provides innovative vaping experiences.

Ethris Initiates First-in-Human Dosing in Phase 1 Study of ETH47 for the Treatment of Virus-Induced Asthma

Retrieved on: 
Monday, December 18, 2023
LNP, RNA, Biotechnology, Messenger, Lung, Snap, Vaccine, Respiratory failure, Trial of the century, Inhalation, Pharmacokinetics, Asthma, SARS-CoV-2, Patient, Safety, Therapy

ETH47 was also designed to be administered locally to the lung through inhalation or nasal spray using the company’s proprietary Stabilized NanoParticle (SNaP) LNP platform.

Key Points: 
  • ETH47 was also designed to be administered locally to the lung through inhalation or nasal spray using the company’s proprietary Stabilized NanoParticle (SNaP) LNP platform.
  • The Phase 1 study will primarily evaluate ETH47’s safety and tolerability in healthy participants.
  • The program, although initially focused on virus-induced asthma, has the potential to be applied for pandemic preparedness against influenza and SARS-CoV-2 due to its broad applicability.
  • The study will contain 3 parts based on the type of delivery of ETH47, which includes nasal, inhaled and a nasal/inhaled combination.

Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives

Retrieved on: 
Monday, November 27, 2023
Recce, Ross River virus, Simplex, ASX, Government, RCE, Klebsiella pneumoniae, PCT, Virus, Burn, Administration, Streptococcus pneumoniae, Patent, Disease, Staphylococcus aureus, Infection, Gonorrhea, Canada Revenue Agency, Inhalation, Shingles, Pseudomonas aeruginosa, Biology, COVID-19, Streptococcus pyogenes, Viral, EBV, Escherichia coli, HIV, Coronavirus, SARS-CoV-2, Cytomegalovirus, Staphylococcus, Urinary tract infection, Bacteria, Neisseria meningitidis, HCMV, Science, Skin, Pharmaceutical industry

SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We thank the Canadian Government for their recognition of the significant potential of Recce’s New Class of Anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • In July 2023, the Company received an AUD $98,428 R&D Rebate from the Canadian Government, under the Scientific Research & Experimental Development (SR&ED) Tax Incentive program.
  • The program is administered by the Canada Revenue Agency and is aimed at incentivizing businesses to conduct R&D in Canada, encouraging innovation and technological advancements.

Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

Retrieved on: 
Monday, November 20, 2023
Inhalation, PAH, Apoptosis, PVR, Therapy, Pharmacokinetics, Patient, Safety, Orthostatic hypertension, Pharmaceutical industry

WALTHAM, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) Phase 2b/Phase 3 study evaluating AV-101, a novel dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), has completed enrollment at 202 adult patients. Aerovate expects to report topline data from the Phase 2b portion of the trial in June 2024. In addition, the first patient has been enrolled in the Phase 3 portion of IMPAHCT.

Key Points: 
  • Aerovate expects to report topline data from the Phase 2b portion of the trial in June 2024.
  • In addition, the first patient has been enrolled in the Phase 3 portion of IMPAHCT.
  • “The completion of enrollment in the Phase 2b portion of the trial marks an exciting milestone for Aerovate and for people living with PAH,” said Tim Noyes, Chief Executive Officer at Aerovate Therapeutics.
  • The Phase 2b primary endpoint of IMPAHCT is the placebo corrected change from baseline in pulmonary vascular resistance (PVR).

NFL Star Rob Gronkowski and Anivive Lifesciences Join Congressional Leaders on Capitol Hill to Combat the Rising Threat of Valley Fever

Retrieved on: 
Tuesday, December 19, 2023
Spore, Pet, Risk, Gronk, Infection, Research, Fungus, FDA, University, Vaccine, Disease, Health, PRV, Human, Congress, Inhalation, Dog, Coccidioidomycosis, Animal, Fungal infection, Climate change, Tropical disease, NFL, Public, Super Bowl, USDA, Coccidioides, Veterinarian, Military personnel, Southwestern United States, Soil

WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- On Capitol Hill last Tuesday, NFL Icon and 4-time Super Bowl Champion Rob Gronkowski and Senators Mark Kelly, Kyrsten Sinema, Markwayne Mullin, and Representative David Schweikert led an event focused squarely on the rising challenge of Valley Fever. Intensified by climate change, this fungal infection is not only a burgeoning public health concern in the American Southwest but also a significant economic burden, costing the U.S. healthcare system an estimated $3.9 billion annually.

Key Points: 
  • - Capitol Hill puts Valley fever in the spotlight just in time as Anivive's canine vaccine is under regulatory review.
  • - Congress introduced 4 bills that aim to fast-track the FDA review of Valley fever solutions and authorize $500 million to support fungal disease initiatives.
  • WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- On Capitol Hill last Tuesday, NFL Icon and 4-time Super Bowl Champion Rob Gronkowski and Senators Mark Kelly, Kyrsten Sinema, Markwayne Mullin, and Representative David Schweikert led an event focused squarely on the rising challenge of Valley Fever.
  • Valley Fever, a serious fungal infection caused by the soil-dwelling Coccidioides, results in tens of thousands of human cases each year.

TILT Holdings Reports Third Quarter 2023 Results

Retrieved on: 
Monday, November 13, 2023
Sale, Chinese New Year, EBITDA, Internal Revenue Service, Average revenue per user, Interim, Breast cancer, Breast Cancer Awareness Month, NEO, Chairperson, Permanent, Flower, TILT, Note, Inhalation, Elevate, Partnership, Female

PHOENIX, Nov. 13, 2023 (GLOBE NEWSWIRE) -- TILT Holdings Inc .

Key Points: 
  • PHOENIX, Nov. 13, 2023 (GLOBE NEWSWIRE) -- TILT Holdings Inc .
  • “These various initiatives led to double-digit revenue growth in the quarter, a near 20% reduction of operating expense, and an increase in adjusted EBITDA.
  • Mr. Conder is a member of TILT’s Board of Directors (“Board”) and was the Interim Chief Executive Officer from April 2023 until September 2023.
  • TILT management will host a conference call today at 5:00 p.m. Eastern time to discuss its business strategy and financial results.

Ethris and Heqet Therapeutics Announce Collaboration to Develop RNA-based Therapeutics for Heart Attack and Heart Failure

Retrieved on: 
Monday, November 13, 2023
Snap, Therapy, Small RNA, Regeneration, Tissue, Biotechnology, Vaccination, Patient, Myocardial infarction, Regenerative medicine, Vaccine, Heqet, Heart failure, Inhalation, LNP, Cardiac muscle, Death, Cell, RNA, Pharmaceutical industry

Under the terms of the agreement, Heqet Therapeutics will lead the development of the program, while Ethris will provide its proprietary Stabilized NanoParticle (SNaP) LNP platform to deliver ncRNA payloads to the heart tissue.

Key Points: 
  • Under the terms of the agreement, Heqet Therapeutics will lead the development of the program, while Ethris will provide its proprietary Stabilized NanoParticle (SNaP) LNP platform to deliver ncRNA payloads to the heart tissue.
  • "Our RNA delivery platform was designed to deliver any type of RNA payload to a broad range of tissues," said Dr. Carsten Rudolph, CEO of Ethris.
  • Under the terms of the collaboration agreement, Ethris and Heqet will operate under a comprehensive commercial agreement, which encompasses various milestone and royalty payments.
  • By harnessing Ethris' SNaP LNP platform for precise delivery, Heqet aims to test the efficacy of its ncRNA candidates to stimulate cardiac regeneration in patients with myocardial infarction and heart failure.